AstraZeneca (NYSE:AZN) and collaboration partner Merck (NYSE:MRK) announce that the FDA has approved LYNPARZA for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen.
The approval follows the recommendation by the FDA Oncologic Drugs Advisory Committee on Dec. 17 for LYNPARZA in this indication.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.